Allaway HCM, Chizen DR, Adams GP, et al. (2017) Effects of a single 20 mg dose of letrozole on ovarian function post dominant follicle selection: An exploratory randomized controlled trial. J Ovarian Res 10:6. http://doi.org/10.1186/s13048-017-0303-x
Alshehre SM, Duffy S, Jones G, et al. (2020) A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain. Reprod Biol Endocrinol 18:28. http://doi.org/10.1186/s12958-020-00586-z
Blumenfeld Z (2019) Fertility preservation using GnRH agonists: Rationale, possible mechanisms, and explanation of controversy. Clin Med Insights Reprod Health 13:1179558119870163. http://doi.org/10.1177/1179558119870163
Bober SL, Fine E, Recklitis CJ (2020) Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): A clinical intervention for young breast cancer survivors. J Cancer Surviv 14:26-30. http://doi.org/10.1007/s11764-019-00800-x
Davis SR, Robinson PJ, Jane F, et al. (2018) Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 103:4146-4154. http://doi.org/10.1210/jc.2018-01345
DeSantis CE, Ma J, Gaudet MM, et al. (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69:438-451. https://doi.org/10.3322/caac.21583
Fan L, Strasser-Weippl K, Li JJ, et al. (2014) Breast cancer in China. Lancet Oncol 15(7):e279-e289. https://doi.org/10.1016/S1470-2045(13)70567-9
Flynn KE, Reese JB, Jeffrey D, et al. (2012) Patient experiences with communication about sex during and after treatment for cancer. Psychooncology 21:594-601. http://doi: 10.1002/pon.1947
Francis PA, Pagani O, Fleming GF, et al. (2018) SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379(2):122-137. http://doi.org/10.1056/NEJMoa1803164
Francis PA, Regan MM, Fleming GF, et al. (2015) SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436-446. http://doi.org/10.1056/NEJMoa1412379
Fugger G, Dold M, Bartova L, et al. (2019) Major depression and comorbid diabetes -Findings from the European Group for the Study of Resistant Depression. Prog Neuropsychopharmacol Biol Psychiatry 94:109638. http://doi.org/10.1016/j.pnpbp.2019.109638
Gandhi C, Butler E, Pesek S, et al. (2019) Sexual dysfunction in breast cancer survivors: Is it surgical modality or adjuvant therapy? Am J Clin Oncol 42:500-506. http://doi.org/10.1097/COC.0000000000000552
Hsieh AH, Kichenadasse G, Vatandoust S, et al. (2016) Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer. Intern Med J 46:1153-1159. http://doi.org/10.1111/imj.1316
Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, et al. (2019) Treatment of breast cancer with gonadotropin-releasing hormone analogs. Front Oncol 9:943. http://doi.org/10.3389/fonc.2019.00943
Hummel SB, Hahn DEE, van Lankveld JJDM, et al. (2017) Factors associated with specific diagnostic and Statistical Manual of Mental Disorders, Fourth Edition sexual dysfunctions in breast cancer survivors: A study of patients and their partners. J Sex Med 14:1248-1259. http://doi.org/10.1016/j.jsxm.2017.08.004
Kuehn R, Casaubon J, Raker C, et al. (2019) Sexual dysfunction in survivorship; the impact of menopause and endocrine therapy. Ann Surg Oncol 26:3159-3165. http://doi.org/10.1245/s10434-019-07552-z
Lan B, Jiang S, Li T, et al. (2020) Depression, anxiety, and their associated factors among Chinese early breast cancer in women under 35 years of age: A cross sectional study. Curr Probl Cancer 100558. http://doi.org/10.1016/j.currproblcancer.2020.100558
Li L, Yang B, Li H, et al. (2019) Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): A study protocol. BMJ Open 9(12):e032945. http://doi.org/10.1136/bmjopen-2019-032945
Maciejewska-Jeske M, Szeliga A, Męczekalski B (2018) Consequences of premature ovarian insufficiency on women’s sexual health. Prz Menopauzalny. 17(3):127-130. http://doi.org/10.5114/pm.2018.78557
Mahmoud R, Wainwright SR, Chaiton JA, et al. (2016) Ovarian hormones, but not fluoxetine, impart resilience within a chronic unpredictable stress model in middle-aged female rats. Neuropharmacology 107:278-293. http://doi.org/10.1016/j.neuropharm.2016.01.033
Metwally IH, Hamdy O, Elbalka SS, et al. (2019) Oophorectomy as a hormonal ablation therapy in metastatic and recurrent breast cancer: Current indications and results. Indian J Surg Oncol 10:542-546. http://doi.org/10.1007/s13193-019-00938-1
Moore HC, Unger JM, Phillips KA, et al., POEMS/S0230 Investigators (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Me 372:923-932. http://doi.org/10.1056/NEJMoa1413204
Nguyen TV, Reuter JM, Gaikwad NW, et al. (2017) The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: Effects of estradiol and progesterone addback. Transl Psychiatry 7(8):e1193. http://doi.org/10.1038/tp.2017.146
Nourmoussavi M, Pansegrau G, Popesku J, et al. (2017) Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. Cancer Treat Rev 55:26-35. http://doi.org/10.1016/j.ctrv.2017.02.005
Pagani O, Francis PA, Fleming GF, et al. SOFT and TEXT Investigators and International Breast Cancer Study Group (2019) Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TEXT and SOFT. J Clin Oncol 38:1293-1303.http://doi.org/10.1200/JCO.18.01967
Park EM, Gelber S, Rosenberg SM, et al. (2018) Anxiety and depression in young women with metastatic breast cancer: A cross-sectional study. Psychosomatics 59:251-258. http://doi.org/10.1016/j.psym.2018.01.007
Park YH, Kim TY, Kim GM, et al.; Korean Cancer Study Group (KCSG). (2019) Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 20:1750-1759. http://doi.org/10.1016/S1470-2045(19)30565-0
Pooley AE, Benjamin RC, Sreedhar S, et al. (2018) Sex differences in the traumatic stress response: The role of adult gonadal hormones. Biol Sex Differ 9(1):32. http://doi.org/10.1186/s13293-018-0192-8
Recchia F, Candeloro G, Rosselli M, et al. (2015) Adjuvant ovarian suppression, high-dose chemotherapy and immunotherapy for premenopausal patients with high-risk breast cancer. Anticancer Res; 35:6847-6853.Regan MM, Fleming GF, Walley B, et al. (2019) Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: Lights and shadows. J Clin Oncol 37(11):862-866. http://doi.org/10.1200/JCO.18.02433
Robinson PJ, Bell RJ, Christakis MK, et al. (2017) Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: An observational study. J Sex Med 14:1566-1574. http://doi.org/10.1016/j.jsxm.2017.09.018
Sa-Nguanraksa D, Krisorakun T, Pongthong W, et al. (2019) Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. Mol Clin Oncol 11:517-522. http://doi.org/10.3892/mco.2019.1913
Senkus E, Gomez H, Dirix L, et al. (2014) Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psycho-Oncology; 23(2):173-182. http://doi.org/10.1002/pon.3384
Silvestris E, Dellino M, Cafforio P, et al. (2020) Breast cancer: An update on treatment-related infertility. J Cancer Res Clin Oncol 146:647-657. http://doi.org/10.1007/s00432-020-03136-7
Soldera SV, Ennis M, Lohmann AE, et al. (2018) Sexual health in long-term breast cancer survivors. Breast Cancer Res Treat 172:159-166. http://doi.org/10.1007/s10549-018-4894-8
Stabile C, Goldfarb S, Baser RE, et al. (2017) Sexual health needs and educational intervention preferences for women with cancer. Breast Cancer Res Treat 165:77-84. http://doi.org/10.1007/s10549-017-4305-6
Stuursma A, van Driel CMG, Wessels NJ, et al. (2018) Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy. Maturitas 111:69-76. http://doi.org/10.1016/j.maturitas.2018.01.012
Tong J, Zhang C, Zhang L, et al. (2020) Analysis of low sexual desire in Chinese women: A national population-based epidemiological survey in mainland China. Sex Health 17:61-68. http://doi.org/10.1071/SH19097
Xia J, Tang Z, Wu P, et al. (2019) Use of item response theory to develop a shortened version of the EORTC QLQ-BR23 scales. Sci Rep 9:1764. http://doi.org/10.1038/s41598-018-37965-x
Yeo W, Ueno T, Lin C, et al. (2019) Treating HR+/HER2—breast cancer in premenopausal Asian women: Asian breast cancer cooperative group 2019 consensus and position on ovarian suppression. Breast Cancer Res Treat. 177:549-559. https://doi.org/10.1007/s10549-019-05318-5.
Zhang C, Cui L, Zhang L, et al. (2017) Sexual activity and function assessment in middle-aged Chinese women using the female sexual function index. Menopause 24:669-676. http://doi.org/10.1097/GME.0000000000000812
Zhang P, Li CZ, Jiao GM, et al. (2017) Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials. Eur J Surg Oncol 43:1161-1172. http://doi.org/10.1016/j.ejso.2016.11.011
Zhang Y, Chen Y, Ma L (2018) Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 47:1-5. http://doi.org/10.1016/j.jocn.2017.09.022